A Systematic Review of Analytical Profiles of SGLT2 Inhibitors and their Combinations for Treatment of Type 2 Diabetes Mellitus / Niyatee Savaikar Thakor, Sunil Vishvanath Amrutkar
The frequency of Type 2 Diabetes Mellitus worldwide is rising rapidly and is estimated to reach 4.4% of the world’s population or about 366 million people by 2030. In the view of National Diabetes Statistics report 2017, 30.3 million people have diabetes in the United States (9.4%) of total population, out of which, 23.1 million are diagnosed and 7.2 million (23.8%) people with Diabetes are undiagnosed. One of the recently introduced therapeutic classes is Sodium Glucose co- Transporter 2 (SGLT2) Inhibitors. Since 2010 USFDA has approved 6 single dose and 7 fixed dose combinations for treatment of Type 2 Diabetes Mellitus. SGLT2 Inhibitors such as Canagliflozin, Dapagliflozin and Empagliflozin are in combinations with most of the dosage forms. This article reviews published analytical methods reported so far in the literature to find SGLT2 inhibitors. They include various techniques like spectrophotometry, high-performance liquid chromatography, liquid chromatography-electrospray ionization-tandem mass spectrometry and high-performance thin layer chromatography for their routine, impurity profiling and stability indicating determination in different pharmaceutical matrices.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Current pharmaceutical analysis - 15(2019), 7, Seite 681- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thakor, Niyatee SavaikarNiyatee Savaikar [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (13 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL00102521X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL00102521X | ||
| 003 | DE-627 | ||
| 005 | 20231128165545.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL00102521X | ||
| 035 | |a (KFL)prod_DARH_.01BBBF6A75DE45EF6914720067C3B9FD85A78D1D | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Thakor, Niyatee SavaikarNiyatee Savaikar |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Systematic Review of Analytical Profiles of SGLT2 Inhibitors and their Combinations for Treatment of Type 2 Diabetes Mellitus |c Niyatee Savaikar Thakor, Sunil Vishvanath Amrutkar |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (13 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The frequency of Type 2 Diabetes Mellitus worldwide is rising rapidly and is estimated to reach 4.4% of the world’s population or about 366 million people by 2030. In the view of National Diabetes Statistics report 2017, 30.3 million people have diabetes in the United States (9.4%) of total population, out of which, 23.1 million are diagnosed and 7.2 million (23.8%) people with Diabetes are undiagnosed. One of the recently introduced therapeutic classes is Sodium Glucose co- Transporter 2 (SGLT2) Inhibitors. Since 2010 USFDA has approved 6 single dose and 7 fixed dose combinations for treatment of Type 2 Diabetes Mellitus. SGLT2 Inhibitors such as Canagliflozin, Dapagliflozin and Empagliflozin are in combinations with most of the dosage forms. This article reviews published analytical methods reported so far in the literature to find SGLT2 inhibitors. They include various techniques like spectrophotometry, high-performance liquid chromatography, liquid chromatography-electrospray ionization-tandem mass spectrometry and high-performance thin layer chromatography for their routine, impurity profiling and stability indicating determination in different pharmaceutical matrices | ||
| 700 | 1 | |a Amrutkar, Sunil Vishvanath |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical analysis |d Sharjah, U.A.E. : Bentham Science Publ., 2005 |g 15(2019), 7, Seite 681- |h Online-Ressource |w (DE-627)KFL000006440 |w (DE-600)2216923-4 |w (DE-576)306832917 |x 1875-676X |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2019 |g number:7 |g pages:681- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-4129&volume=15&issue=7&spage=681 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_02 | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2019 |e 7 |h 681- | ||